Lanreotide + saline
Phase 3Completed 3 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Trial Timeline
Sep 19, 2014 → Jul 31, 2019
NCT ID
NCT02127437About Lanreotide + saline
Lanreotide + saline is a phase 3 stage product being developed by Ipsen for Autosomal Dominant Polycystic Kidney Disease (ADPKD. The current trial status is completed. This product is registered under clinical trial identifier NCT02127437. Target conditions include Autosomal Dominant Polycystic Kidney Disease (ADPKD.
What happened to similar drugs?
1 of 4 similar drugs in Autosomal Dominant Polycystic Kidney Disease (ADPKD were approved
Approved (1) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02127437 | Phase 3 | Completed |
Competing Products
19 competing products in Autosomal Dominant Polycystic Kidney Disease (ADPKD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABBV-CLS-628 + Placebo | AbbVie | Phase 2 | 42 |
| AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B | AstraZeneca | Phase 1 | 36 |
| Placebo + Everolimus | Novartis | Approved | 43 |
| Octreotide + Placebo | Novartis | Phase 2/3 | 38 |
| Everolimus + Calcineurin inhibitors maintenance | Novartis | Phase 3 | 40 |
| Bosutinib + Bosutinib + Placebo | Pfizer | Phase 2 | 35 |
| VX-407 | Vertex Pharmaceuticals | Phase 2 | 42 |
| VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE | Vertex Pharmaceuticals | Phase 1 | 33 |
| VX-407 + Placebo + Midazolam + VX-407 | Vertex Pharmaceuticals | Phase 1 | 29 |
| VX-407 + Placebo | Vertex Pharmaceuticals | Phase 1 | 33 |
| Tesevatinib | Sanofi | Phase 1/2 | 32 |
| Tesevatinib + Placebo | Sanofi | Phase 2 | 35 |
| Venglustat + Placebo | Sanofi | Phase 2/3 | 30 |
| Bardoxolone methyl oral capsule + Placebo oral capsule | Biogen | Phase 3 | 29 |
| KB105 | Krystal Biotech | Phase 2 | 28 |
| KB105 | Krystal Biotech | Phase 1/2 | 25 |
| Lixivaptan + Placebo | Centessa Pharmaceuticals | Phase 3 | 29 |
| GLPG2737 + Placebo | Galapagos | Phase 2 | 21 |
| QR-1123 | ProQR | Phase 1/2 | 26 |